Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

Dong Hoe Koo, Hee Jin Lee, Jin Hee Ahn, Dok Hyun Yoon, Sung Bae Kim, Gyungyub Gong, Byung Ho Son, Sei Hyun Ahn, Kyung Hae Jung

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Trastuzumab (H)-based chemotherapy has been an active treatment in patients with HER2-positive breast cancer; however, primary and secondary resistance has occurred in patients treated with H alone or in combination with chemotherapy. Biomarkers were searched using tissue microarrays (TMA) in HER2-positive advanced breast cancer patients treated with H and paclitaxel (P) combination chemotherapy between October 2004 and August 2010. Tumor blocks were analyzed for Tau-protein, beta-III tubulin, PTEN, p27, IGF-1R, c-Met, CD44, and MUC4 by immunohistochemical (IHC) analysis. The correlation between IHC status and clinical outcomes, including response rate (RR), progression free survival (PFS), and overall survival (OS), was investigated. With a median follow-up duration of 54.1 months (range, 42.3–72.7 months), 65 patients received H + P chemotherapy. The overall RR was 63 % (95 % CI, 51–75 %), and seven patients (11 %) with high Tau/low PTEN expression showed a significantly lower RR (14 % vs. 69 %; p = 0.008). The odds ratio for a poor response was 13.3 (95 % CI, 1.5–119.0; p = 0.020). In addition, patients with high Tau/low PTEN showed a trend of poor survival in terms of PFS (6.6 months vs. 9.6 months, p = 0.052). Subsequent multivariate analysis showed that high Tau/low PTEN (hazard ratio [HR] 2.40, 95 % CI, 1.06–5.47; p = 0.037) was the poor prognostic factor independently associated with PFS after adjusting for possible confounding factors such as recurrence/metastasis, age, performance status, visceral metastasis, and hormone receptor status. High Tau-protein and low PTEN expression showed a significant association with poor response to H + P chemotherapy in patients with HER2-positive advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)5865-5871
Number of pages7
JournalTumor Biology
Issue number8
StatePublished - Aug 24 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015, International Society of Oncology and BioMarkers (ISOBM).


  • Breast neoplasms
  • PTEN
  • Paclitaxel
  • Resistance
  • Tau
  • Trastuzumab


Dive into the research topics of 'Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer'. Together they form a unique fingerprint.

Cite this